Narratives are currently in beta
Active Pipeline:
HG-CT-1 - Hemogenyx CAR-T for R/R AML + expanding to pediatrics in H1 2025 targeting FLT3 which has recently been proven as an extremely promising and effective target. Significant interest in CAR-T treatments with each treatment 200k+, licensing deals in the range of 500m->1bn+ (including milestone payments)
CDX - Building on same FLT3 target expands use of bi-specific antibody to a whole range of blood borne cancers and diseases including auto-immune. Off the shelf + cheap to manufacture, success of HG-CT-1 will be of significant importance here.
CBR - Potential to cure any virus + range of cancers and other conditions, recent breakthroughs include nasal delivery and ability to pass brain blood barrier. Scope for interest by US Defense in the fight against Bio terrorism and Disease X.
Target market for each of the above is in the billions, current mCap = 14m.
Debt = Zero.
Reason for current low mCap? Company has relied on a small pool of UK investors to fundraise for the past several years, each increment has relied on same pool whom have taken to short selling and dumping to increase dilution and discounts they took and made it hard for company to fund raise. Company have broken away from this investor pool and engaged US based investment brokers, expect to see US based investment in the near future + potential for near term grants/JV and licensing opportunities.
How well do narratives help inform your perspective?
